Lachowiez CA., Loghavi S., Zeng Z., Tanaka T., Kim YJ., Uryu H., Turkalj S., Jakobsen NA., Luskin MR., Duose DY., Tidwell RSS., Short NJ., Borthakur G., Kadia TM., Masarova L., Tippett GD., Bose P., Jabbour EJ., Ravandi F., Daver NG., Garcia-Manero G., Kantarjian H., Garcia JS., Vyas P., Takahashi K., Konopleva M., DiNardo CD.

<p>Supplementary protocol for "Phase Ib/II Investigator Initiated Study of the IDH1-mutant inhibitor ivosidenib (AG120) with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies"</p>

Supplementary Protocol from A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies

DOI

Type

Publication Date